Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.

Papay K, Xie SX, Stern M, Hurtig H, Siderowf A, Duda JE, Minger J, Weintraub D.

Neurology. 2014 Aug 26;83(9):826-33. doi: 10.1212/WNL.0000000000000729. Epub 2014 Jul 18.

2.

Impulse control and related disorders in Mexican Parkinson's disease patients.

Rodríguez-Violante M, González-Latapi P, Cervantes-Arriaga A, Camacho-Ordoñez A, Weintraub D.

Parkinsonism Relat Disord. 2014 Aug;20(8):907-10. doi: 10.1016/j.parkreldis.2014.05.014. Epub 2014 Jun 5.

PMID:
24935236
3.
4.

A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania.

Grant JE, Kim SW, Odlaug BL.

Biol Psychiatry. 2009 Apr 1;65(7):600-6. doi: 10.1016/j.biopsych.2008.11.022. Epub 2009 Feb 12.

PMID:
19217077
5.

Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.

Weintraub D, Papay K, Xie SX.

Neurology. 2015 Mar 31;84(13):1386-7. No abstract available.

PMID:
25992402
6.

Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.

Liang JW, Shanker VL, Groves M.

Neurology. 2015 Mar 31;84(13):1386-7. No abstract available.

PMID:
25992401
7.

Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.

Galduróz JC, Ramos AC, Santos-Galduróz RF.

Neurology. 2015 Mar 31;84(13):1386-7. doi: 10.1212/WNL.0000000000001458. No abstract available.

PMID:
25825466
8.

Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling.

Kim SW, Grant JE, Adson DE, Shin YC.

Biol Psychiatry. 2001 Jun 1;49(11):914-21.

PMID:
11377409
9.

Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease.

Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stern MB, Voon V.

Mov Disord. 2009 Jul 30;24(10):1461-7. doi: 10.1002/mds.22571.

10.

Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability.

Papay K, Mamikonyan E, Siderowf AD, Duda JE, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Weintraub D.

Parkinsonism Relat Disord. 2011 Mar;17(3):153-5. doi: 10.1016/j.parkreldis.2010.11.015. Epub 2010 Dec 24.

11.

Increased risk of impulse control symptoms in Parkinson's disease with REM sleep behaviour disorder.

Fantini ML, Macedo L, Zibetti M, Sarchioto M, Vidal T, Pereira B, Marques A, Debilly B, Derost P, Ulla M, Vitello N, Cicolin A, Lopiano L, Durif F.

J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):174-9. doi: 10.1136/jnnp-2014-307904. Epub 2014 Jul 8.

PMID:
25006210
12.

Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale.

Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A.

Mov Disord. 2012 Feb;27(2):242-7. doi: 10.1002/mds.24023. Epub 2011 Dec 1.

13.

Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study.

Dannon PN, Lowengrub K, Musin E, Gonopolski Y, Kotler M.

J Clin Psychopharmacol. 2005 Dec;25(6):593-6.

PMID:
16282845
14.

[Impulse control disorders in Parkinson's disease: A cohort of 35 patients].

Carrière N, Kreisler A, Dujardin K, Destée A, Defebvre L.

Rev Neurol (Paris). 2012 Feb;168(2):143-51. doi: 10.1016/j.neurol.2011.07.010. Epub 2011 Nov 29. French.

PMID:
22129474
15.

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.

Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.

Mov Disord. 2013 Nov;28(13):1838-46. doi: 10.1002/mds.25561. Epub 2013 Jul 12.

PMID:
23853029
16.

Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, Montastruc JL, Rascol O.

Clin Neuropharmacol. 2012 Nov-Dec;35(6):261-5. doi: 10.1097/WNF.0b013e31826e6e6d.

PMID:
23123689
17.

Problematic Internet use in Parkinson's disease.

Wu K, Politis M, O'Sullivan SS, Lawrence AD, Warsi S, Lees A, Piccini P.

Parkinsonism Relat Disord. 2014 May;20(5):482-7. doi: 10.1016/j.parkreldis.2014.01.019. Epub 2014 Feb 5.

PMID:
24582704
18.

Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.

Mamikonyan E, Xie SX, Melvin E, Weintraub D.

Mov Disord. 2015 Jun;30(7):912-8. doi: 10.1002/mds.26236. Epub 2015 Apr 25.

PMID:
25914281
19.

Zonisamide in managing impulse control disorders in Parkinson's disease.

Bermejo PE, Ruiz-Huete C, Anciones B.

J Neurol. 2010 Oct;257(10):1682-5. doi: 10.1007/s00415-010-5603-7. Epub 2010 May 28.

PMID:
20509031
20.

Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson's disease.

Pontieri FE, Assogna F, Pellicano C, Cacciari C, Pannunzi S, Morrone A, Danese E, Caltagirone C, Spalletta G.

Eur Neuropsychopharmacol. 2015 Jan;25(1):69-76. doi: 10.1016/j.euroneuro.2014.11.006. Epub 2014 Nov 18.

PMID:
25435085
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk